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ABSTRACT
Background NHS England recommends non- 
invasive continuous positive airway pressure (CPAP) 
as a possible treatment for type 1 respiratory failure 
associated with COVID-19 pneumonitis, either to 
avoid intubation or as a ceiling of care. However, data 
assessing this strategy are sparse, especially for 
the use of CPAP as a ceiling of care, and particularly 
when delivered outside of a traditional critical care 
environment. We describe a cohort of patients from 
Liverpool, UK, who received CPAP on a dedicated 
respiratory surge unit at the start of the second wave 
of the COVID-19 pandemic in UK.
Methods Retrospective cohort analysis of consecutive 
patients receiving CPAP for the treatment of respiratory 
failure secondary to COVID-19 on the respiratory surge 
unit at the Royal Liverpool Hospital, Liverpool, UK from 
21 September until 30 November 2020.
Results 88 patients were included in the analysis. 
56/88 (64%) were deemed suitable for escalation to 
invasive mechanical ventilation (IMV) and received 
CPAP as a trial; 32/88 (36%) received CPAP as a ceiling 
of care. Median age was 63 years (IQR: 56–74) and 
58/88 (66%) were men. Median SpO2/FiO2 immediately 
prior to CPAP initiation was 95 (92–152). Among 
patients for escalation to IMV, the median time on 
CPAP was 6 days (IQR 4–7) and survival at day 30 
was 84% (47/56) with 14/56 (25%) escalated to IMV. 
Of those patients for whom CPAP was ceiling of care, 
the median duration of CPAP was 9 days (IQR 7–11) 
and 18/32 (56%) survived to day 30. Pulmonary 
barotrauma occurred in 9% of the cohort. There were 
no associations found on multivariant analysis that 
were associated with all- cause 30- day mortality.
Conclusions With adequate planning and resource 
redistribution, CPAP may be delivered effectively outside 
of a traditional critical care setting for the treatment of 
respiratory failure due to COVID-19. Clinicians delivering 
CPAP to patients with COVID-19 pneumonitis should be 
alert to the dangers of pulmonary barotrauma. Among 
patients who are for escalation of care, the use of CPAP 
may avoid the need for IMV in some patients. Our data 
support the NHS England recommendation to consider 
CPAP as a ceiling of care.
INTRODUCTION
To date, SARS- CoV-2—the causal agent of 
COVID-19—has infected over 100 million 
people worldwide resulting in over 2 million 
deaths.1 In the UK, 10%–15% of individuals 
with COVID-19 have required admission 
to hospital with the majority experiencing 
varying degrees of type 1 respiratory failure 
and 17% requiring admission to critical 
care.2–4
The optimal modality for respiratory support 
for individuals with COVID-19 who remain 
hypoxic despite standard oxygen therapy 
(administered via nasal cannulae (prongs) or 
Venturi face mask) is uncertain. During the 
early period of the pandemic, practice varied 
considerably with some centres opting for 
early initiation of invasive mechanical venti-
lation (IMV) in a large proportion of patients 
failing on standard oxygen therapy. Early 
reports of high mortality among invasively 
ventilated patients, as well as constraints on 
the availability of critical care beds, prompted 
the increased use of non- invasive continuous 
positive airway pressure (CPAP) ventilation. 
Accordingly, NHS England guidance issued 
in March 2020 suggested that CPAP may be 
Key messages
 ► What is key question: Was providing continuous 
positive airway pressure (CPAP) to patients with 
COVID-19 outside the walls of critical care safe and 
effective in the context of the current pandemic?
 ► What is the bottom line? In this context, CPAP ap-
peared be a safe and effective treatment for type 1 
respiratory failure in COVID-19.
 ► Why read on? Find out which patient population we 
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offered either to avoid the use of IMV or as a ceiling of 
treatment.5
Due to the scale of the pandemic across the UK, in 
many hospitals overwhelming the capacity of critical 
care units, CPAP was often delivered in respiratory surge 
units outside a traditional critical care environment.6–10 
Emerging data from the first wave of the pandemic, 
including from our unit in Liverpool, suggest promising 
outcomes following the use of CPAP in such settings, with 
between 40% and 63% of those patients deemed appro-
priate for full escalation of care avoiding IMV.6–8 10 A large 
prospective study from Italy has also reported positive 
results with 498/778 (62.4%) of patients avoiding intuba-
tion.11Higher C reactive proteins, lower PaO2/FiO2 and 
lower platelet counts were all associated with increased 
risk of CPAP failure.11
Severe COVID-19, however, disproportionately affects 
elderly, frail individuals with chronic comorbid illness. 
For many, IMV may not be offered as it carries a very 
high risk of failure and as such may result in unneces-
sary suffering. For these patients, CPAP may be offered 
as a ceiling of care, although experience is limited and 
reported outcomes variable: in a small cohort of 19 
patients from Huddersfield receiving CPAP as a ceiling 
of care, 84% died8; in another similar small cohort of 28 
patients from Newcastle, 50% died prior to discharge.12
With unprecedented research efforts, the standard 
medical management of COVID-19 has evolved rapidly 
Table 1 Baselines characteristics of patients starting CPAP stratified by escalation status
 
For escalation to IMV (n=56)




Age (median, IQR) 60 (53–65) 76 (64–82) 63 (56–74)
Age (years)
  <50 10 (18%) 1 (3%) 11 (13%)
  50–59 16 (29%) 3 (9%) 19 (22%)
  60–69 22 (39%) 9 (28%) 31 (35%)
  70–79 8 (14%) 8 (25%) 16 (18%)
  ≥80 0 (0)%) 11 (34%) 11 (13%)
Male 39 (70%) 19 (60%) 58 (66%)
BMI (kg/m2) 31 (28–33) 32 (28–36) 31 (28–34)
Pre- hospital symptom duration 9 (7–10) 7 (6–10) 8 (7–10)
Diabetes 17 (30%) 15 (47%) 32 (36%)
Hypertension 24 (43%) 26 (82%) 50 (57%)
Asthma 5 (9%) 4 (13%) 9 (10%)
COPD 2 (4%) 4 (13%) 6 (7%)
Other cardiac condition 8 (14%) 13 (47%) 21 (24%)
OSA 4 (7%) 1 (3%) 5 (6%)
Other comorbid illness 26 (46%) 22 (69%) 48 (55%)
Smoked
  Never 38 (68%) 18 (56%) 56 (64%)
  Ever 14 (25%) 13 (41%) 27 (30%)
  Current 4 (7%) 1 (3%) 5 (6%)
Clinical frailty scale22 1 (1–2) 4 (3–5) 2 (1–3)
Mortality 4C Score23 19% (12%–27%) 41% (24%–52%) 23% (14%–40%)
Exercise tolerance (m)†
  >1500 37 (66%) 2 (6%) 39 (44%)
  >1000 13 (23%) 4 (13%) 17 (19%)
  >500 4 (7%) 9 (28%) 13 (15%)
  >100 1 (2%) 2 (6%) 3 (3%)
  >50 1 (2%) 5 (15%) 6 (7%)
  <50 0 (0%) 10 (31%) 10 (11%)
*CPAP as ceiling care. The patient was not deemed clinically appropriate for mechanical ventilation.
†Self- reported.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; IMV, invasive 
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to incorporate treatments such as dexamethasone and, in 
some circumstances, remdesivir and IL6 antagonists. The 
optimal modality of respiratory support, and anticipated 
outcomes, may vary with therapeutic advances. Within 
this context of evolving medical management, we report 
the outcomes of a cohort of patients hospitalised during 
the second wave of the COVID-19 pandemic in the UK 
who received CPAP within a respiratory surge unit either 
as a trial to avoid IMV or as a ceiling of care.
METHODS
Setting and design
We conducted a retrospective cohort analysis of patients 
who received CPAP for the treatment of respiratory 
failure secondary to COVID-19 on the respiratory surge 
unit of the Royal Liverpool Hospital (part of Liverpool 
University Hospitals NHS Foundation Trust) from 21 
September 2020 (when the surge of admissions during 
the UK second wave necessitated reopening the unit) 
until 30 November 2020. Anonymised data were collected 
in real time by clinicians involved in patients’ care as part 
of a service evaluation project registered with the Trust’s 
Clinical Audit service (CAMS 9942).
Participants
All patients admitted to the respiratory surge unit who 
were treated with CPAP for type 1 respiratory failure 
secondary to COVID-19 were included in the analysis, 
regardless of escalation status, medical history or antic-
ipated prognosis. All patients had a positive nasopharyn-
geal PCR swab for SARS- CoV-2 and/or a clinical diag-
nosis of COVID-19.
Patient and public involvement
Neither the patients nor the public were involved in the 
design or implementation of this study.
Procedures
The redistribution of resources required to establish the 
respiratory surge unit has been previously described.10 13 
In brief, the unit was established in one of the hospital’s 
infectious disease (ID) isolation wards with each patient 
accommodated in an individual negative pressure room 
and all staff wearing appropriate personal protective 
equipment.14 A multidisciplinary team consisting of ID 
and respiratory medical staff, ID and respiratory nurses 
and a respiratory physiotherapist, supported by crit-
ical care clinicians and outreach teams, was established 
to deliver the service. Extensive training in the theory 
and practicalities of CPAP delivery—building on the 
approach from the first wave—was delivered to all non- 
respiratory staff by the specialist respiratory nurses and 
physiotherapist.
Patients were started on CPAP based on clinical assess-
ment. Local guidelines suggested that CPAP should be 
considered—and discussed with the critical care team—
when fractional inspired oxygen concentration (FiO2) 
of 60% or more was required to maintain peripheral 
oxygen saturations at 92% or greater. A standard electri-
cally powered non- invasive ventilator (Philips A30) was 
utilised with wall oxygen entrained into the circuit as per 
the British Thoracic Society (BTS) guidelines.15 These elec-
trically powered machines were repurposed solely for use 
during the COVID-19 pandemic on the respiratory surge 
unit. Within ICU, CPAP was delivered via high- flow devices. 
CPAP was delivered in accordance to local policy. CPAP was 
started at pressure of 5 cmH2O, increasing to CPAP to 10 
cmH2O within the first hour if required, and thereafter only 
escalated to a maximum of 12.5 cmH2O following discus-
sion with senior medical or specialist staff.13 Oxygen up to 
30 L/min was entrained into the circuit using a standard 
oxygen port and green tubing to maintain SpO2 of between 
92% and 96%. A non- vented oral- nasal mask was used and 
changed to full face (visor style) masks if required. A viral 
filter was placed upstream of the exhalation port in the 
circuit and was changed every 24 hours.14
Table 2 Physiological parameters at CPAP initiation stratified by escalation status
Variable
For escalation to IMV
(n=56)




Respiratory rate pre- CPAP (median, IQR) 30 (25–36) 29 (24–34) 30 (25–35)
Fio2 pre- CPAP (median, IQR) 100 (60–100) 100 (60–100) 100 (60–100)
SpO2 pre- CPAP 93 (91–95) 92 (88–94) 92 (90–95)
SpO2/FiO2 ratio 95 (92–153) 94 (89–151) 95 (92–152)
Initial CPAP (cmH2O) 10 (7.5–10) 10 (7.5–10) 10 (7.5–10)
Maximum CPAP (cmH2O) 10 (7.5–10) 10 (10–10) 10 (8.8–10)
Initial oxygen (L/min) 15 (10–15) 15 (12–18) 15 (10–15)






*CPAP as ceiling care. The patient was not deemed clinically appropriate for mechanical ventilation.
†Others are REMAP- CAP, OSCAR or REALIST.
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Patients were given minimal breaks (oral intake and 
pressure relief only) during the first 36 hours of treat-
ment and if clinically stable, weaning thereafter was proto-
colised (see online supplemental material), with scope 
for tailoring to individual circumstances after specialist 
discussion. For safety reasons, patients were only proned 
if they were able to independently self- prone. Most were 
unable to do this and therefore proning was not used 
extensively within this cohort.
Statistical methods
Continuous variables are reported as mean (with standard 
deviation, SD) or medians (with interquartile range, IQR) 
and categorical data as frequency. Patient characteristics 
and outcomes are stratified by CPAP indication: as a trial 
in patients deemed suitable to escalation to IMV; as a 
ceiling of care. SpO2/FiO2 ratio was calculated as marker 
of severity of acute respiratory distress syndrome (ARDS) 
as arterial lines allowing for regular arterial blood gases 
were not used in this setting.16 Odds ratios (ORs) and 
logistic regression modes were used to determine predic-
tors of 30- day all- cause mortality. Predictors were selected 
a priori. Data were analysed using Stata V.14.2 statistical 
software. Statistical significance was tested at the 5% level.
RESULTS
Patient characteristics and clinical presentation
There was 1042 confirmed SARS- CoV-2 patients diag-
nosed between 21 September and 30 November 2020. 
One hundred and sixteen were admitted to critical care 
and 88 patients received CPAP on the respiratory surge 
unit. Of those 88, 56/88 (64%) were deemed eligible 
for escalation to critical care and IMV and 32/88 (36%) 
received CPAP as a ceiling of care. The median age 
was 63 years (IQR: 56–74) and 58/88 (66%) were male 
(table 1). Those for whom CPAP was the ceiling of care 
were older, with 11/32 (34%) being 80 years or above and 
more frail (median clinical frailty scale 4 (IQR: 3–5) vs 1 
(IQR: 1–2)). Recognised risk factors for severe COVID-19 
were frequent across both groups: hypertension (50/88, 
57%), type 2 diabetes (32/88, 36%), elevated body mass 
index (BMI; median 31; IQR: 28–34). Of those in the 
CPAP as ceiling of care category, 80% of patients had an 
exercise tolerance of 500 m or less.
On admission to the surge unit, most patients were 
receiving oxygen delivered at 15 L/min via a non- 
rebreathe mask (documented as 100% oxygen; median 
pre- CPAP FiO2 was 100% (IQR 60%–100%; table 2). 
Median SpO2 immediately prior to CPAP initiation was 
92% (IQR 90%–95%) with an SpO2/FiO2 ratio of 95 (92–
152). Median starting CPAP (ie, highest airway pressure 
administered within the first hour) was 10 cmH2O (IQR 
7.5–10) and the median oxygen flow rate was 15 L/min 
(10–15 L/min).
Outcomes
Thirty- day outcome data were available for all patients. 
For the overall cohort, 30- day all- cause mortality was 
23/88 (26%; table 3). At the time of writing, all surviving 
patients had been weaned from CPAP or IMV support; 
1/88 (1.1%) patient remains in hospital requiring 
further rehabilitation.
In those who were for full escalation to IMV, the median 
time on CPAP was 6 days (IQR 4–7) and median length of 
hospital stay was 15 days (IQR 10–24). Forty- seven (84%) 
of 56 survived to day 30. Fourteen (25%) of 56 were 
escalated to IMV, of whom 5/14 (36%) survived to day 
30 (figure 1). A further 11/56 (20%) were transferred 
to the critical care unit but did not receive IMV: 6/11 
patients required continued closer nursing supervision 
or delivery of CPAP via hood (which was incompatible 
with CPAP device on ward); 5/11 patients were taken to 
ICU as a precaution because the need for intubation was 
thought to be imminent. Overall, 42/56 (75%) avoided 












42 (75%) 18 (56%) 60 (68%)
Fully weaned from CPAP by
Age (years)
  <50 8 (80%) 1 (100%) 9 (82%)
  50–59 11 (69%) 2 (67%) 13 (68%)
  60–69 17 (77%) 8 (89%) 25 (31%)
  70–79 6 (75%) 2 (25%) 8 (50%)
  ≥80 0 5 (45%) 5 (45%)
Discharged 
home
42 (75%) 18 (56%) 60 (68%)
Increased support at discharge
  LTOT 0 (0%) 3 (17%) 3 (5%)
  New/increased 
POC
0 (0%) 5 (28%) 5 (6%)
Days on CPAP 
(median, IQR)
6 (4–7) 9 (7–11) 6 (4–8)
Length of stay 
(days; median, 
IQR)
13 (9–19) 24 (18–29) 15 (10–24)
Needed CPAP in 
ICU but not IMV
11 (20%) 0 (0%) 11 (13%)
IMV post CPAP 14 (25%) 14 (16%)
Time to IMV 











5 (36%) 5 (36%)
30- day mortality 9 (16%) 14 (44%) 23 (26%)
*CPAP as ceiling care. The patient was not deemed clinically 
appropriate for mechanical ventilation.
CPAP, continuous positive airway pressure; IMV, invasive mechanical 
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IMV. None required long- term oxygen therapy (LTOT) 
at discharge.
Of those patients for whom CPAP was ceiling of care, 
the median duration of CPAP was 9 days (IQR 7–11) and 
the median length of hospital stay in those who survived 
to discharge was 24 days (IQR 18–29). Two patients 
required weaning to high flow oxygen (AIRVO 2 with 
supplemental oxygen) prior to standard wall oxygen. 
Eighteen (56%) of 32 survived to day 30, all of whom 
have been discharged home. Three (17%) of 18 had 
persistent hypoxia requiring LTOT and 5/18 (28%) 
required a new or increased package of care (POC). 
Five (45%) of 11 in the over 80 age group successfully 
weaned and discharged. Only one patient was readmitted 
within 30 days following discharge and has since been 
discharged again back to their normal residence.
Pulmonary barotrauma (pneumothorax, pneumome-
diastinum and surgical emphysema) occurred in 8/88 
(9%) of patients, with 2 requiring intercostal drainage.
Associations with 30-day mortality
In bivariable analysis, those over the age of 80 years were 
at significantly higher odds of death (OR: 12.0; 95% CI: 
1.1 to 128.8) as were those who had an exercise toler-
ance of less than 500 m but greater than 100 m (OR: 
5.3; 95% CI: 1.4 to 20.8) (table 4). The ISARIC mortality 
score was associated with 30- day mortality, with OR 1.03 
(95% CI: 1.0 to 1.1) for each percentage point increase. 
None of the assessed factors were independently associ-
ated with mortality in multivariant analysis in either the 
full or any reduced models (table 4).
DISCUSSION
We present the outcomes of a cohort of patients with 
severe COVID-19 who received CPAP on a respiratory 
surge unit during the second wave of the pandemic in 
the UK. Despite most having severe respiratory failure, 
as demonstrated by a median SpO2/FiO2 ratio of 95 
prior to initiation of CPAP, we report an overall survival 
to 30 days of 74%. Among those eligible for IMV who 
received CPAP as trial, three- quarters avoided IMV and 
84% survived to day 30. Notably, survival to 30 days was 
56% for those who received CPAP as a ceiling a care—a 
group of patients for whom outcome data are presently 
scarce—although morbidity in this group was substantial 
with several requiring LTOT and almost one- third a new 
or increased social care input at discharge.
In the absence of any data from randomised controlled 
trials, the optimal approach to respiratory support in 
COVID-19 is not established. The RECOVERY- RS trial 
compares continued standard oxygen therapy to high- flow 
nasal oxygen and CPAP, although eligibility is restricted 
to those patients deemed suitable to escalation to IMV. 
There is however an emerging but small body of evidence 
from observational series reporting the outcomes of CPAP 
in COVID-19, to which our data contribute. Experience 
on the use of CPAP in Italian centres early in the first 
wave of the global pandemic was mixed. A single- centre 
cohort from early March 2020 reported 90% of patients 
who received CPAP either died or received IMV.17 A large 
multicentre study of 537 patients admitted from March to 
mid- April 2020 reported overall survival following CPAP 
of 66%, although 45% of those patients for escalation to 
IMV—who accounted for 74% of the cohort—received 
IMV.18 During the first wave, centres in the UK reported 
between 40% and 63% patients avoiding mechanical 
ventilation.6–8 10 19 The results presented herein from a 
cohort hospitalised during the second wave in the UK 
suggest improved outcomes. Clearly, there are multiple 
potential explanations, such as evolving standard of 
care including routine use of dexamethasone, improved 
familiarity of medical staff with a novel disease process 
and also more judicious patient selection for non- invasive 
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respiratory support. Nonetheless, the apparent improved 
survival rates coupled with reduced requirement for IMV 
in severe COVID-19 are encouraging.
There is limited data reporting the outcomes of 
patients with COVID-19 receiving CPAP as ward- based 
ceiling of care. The two available case series from the 
UK, both from the first wave of the pandemic, report 
survival rates of 50% and 19% in cohorts of 28 and 19 
patients, respectively.8 12 The multicentre Italian cohort 
mentioned above report 27% survival at 60 days among 
140 patients receiving CPAP as a ceiling of care, although 
results were variable with another centre reporting an 
83% survival rate (53 patients) in those who received 
CPAP.20 Our series with 56% survival rate in this patient 
group compares favourably to these previous reports and 
we suggest supports the current NHS England recom-
mendation to consider offering CPAP as a ceiling of care.
The potential benefits of CPAP must be appropriately 
weighed against its potential burdens. Our data do high-
light a risk of pulmonary barotrauma: 9% of our patients 
developed pneumomediastinum, surgical emphysema or 
pneumothorax. We did not observe barotrauma in asso-
ciation with the use of CPAP during the first wave of the 
pandemic, although it has been reported by other centres 
following the use of both invasive and non- invasive posi-
tive pressure ventilation.21 We encourage clinicians to be 
alert to this as a cause of deterioration on CPAP.
To our knowledge, this is the first description of 
outcomes following CPAP for severe COVID-19 during 
the second wave of the pandemic in the UK and is among 
Table 4 Bi- variant and multiple variant logistic regression of 30- day mortality
Variable
Bivariable analysis Multivariable analysis
OR (95% CI) OR (95% CI)
Age (years)
  <50 1.0 – 1.0 –
  50–59 2.6 0.3 to 27.5 2.6 0.2 to 37.8
  60–69 1.9 0.2 to 18.6 1.8 0.1 to 41.6
  70–79 7.8 0.8 to 76.1 5.4 0.1 to 313.6
  ≥80 12.0 1.1 to 128.8* 9.7 0.1 to 1116.5
Sex
  Male 1.0 – 1.0 –
  Female 0.4 0.1 to 1.3 0.6 0.1 to 3.0
BMI (kg/m2) 0.9 0.9 to 1.0 1.04 0.9 to 1.22
Pre- hospital symptom duration 1.1 0.9 to 1.2 1.1 0.9 to 1.4
Diabetes 0.9 0.3 to 2.4 0.9 0.2 to 38.6
Hypertension 1.3 0.5 to 3.3 2.0 0.3 to 12.0
Asthma 0.3 0.1 to 2.7 2.7 0.2 to 38.6
COPD 0.5 0.1 to 5.0 0.1 0.1 to 1.8
Other cardiac condition 0.9 0.3 to 2.7 1.2 0.2 to 8.4
OSA 2.0 0.3 to 12.6 37.4 1.2 to 1204.8
Other comorbid illness† 0.7 0.3 to 1.8 0.2 0.2 to 1.1
Smoked
  Never 1.0 1.0 –
  Ever/current 1.5 0.6 to 4.0 2.63 0.6 to 12.3
Clinical frailty scale22 1.2 0.9 to 1.6 1.5 0.5 to 5.0
Mortality 4C score23 1.03 1.0 to 1.1* 1.0 0.91 to 1.05
Exercise tolerance (m)‡
  >1500 1.0 – 1.0 –
  >1000 1.9 0.5 to 7.2 2.04 0.3 to 12.0
  >500 5.3 1.4 to 20.8* 5.3 0.53 to 54.8
  >100 2.3 0.2 to 28.9 – –
  >50 0.9 0.1 to 9.1 0.7 0.9 to 1.4
  <50 1.2 0.2 to 6.6 0.2 0.0 to 41.6
*Significant at p<0.05.
†Other significant clinical past medical history.
‡Self- reported.
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the largest UK cohorts described to date. Nevertheless, as 
a retrospective description of a cohort without a control 
group, we recognise that this analysis has inherent limita-
tions. While local guidelines were developed to guide 
the use of CPAP, the decision to offer CPAP represents 
a clinical judgement: we do not describe here outcomes 
of patients who, for example, continued with standard 
oxygen therapy or were directly admitted to critical 
care. Factors such as disease severity, premorbid func-
tional status, critical care bed availability and more 
subtle considerations such as body habitus and work of 
breathing factors were all likely to influence the deci-
sions on whether or not to offer CPAP on the respira-
tory surge unit. The data are derived from a single centre 
which limits generalisability. Pending the availability of 
evidence from randomised controlled trials, however, 
observational data such as these have a role to play both 
in guiding management decisions and, importantly, 
informing discussions with patients and their families.
In conclusion, CPAP represents a feasible and poten-
tially efficacious option for the treatment of type 1 respi-
ratory failure in COVID-19 that—in the context of surges 
of disease that temporarily overwhelm critical care bed 
capacity—may be delivered outside the traditional crit-
ical care, thus relieving pressure on critical care beds. 
Our data support the NHS England recommendation 
to consider CPAP as a ceiling of care for those in whom 
admission to the ICU is not deemed appropriate and can 
inform clinicians and patients in making decisions about 
care.
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